Regression Analysis to Estimate the Factor VIII Activity of Patients with Hemophilia A Without Inhibitor who Received Emicizumab Therapy

BACKGROUND:  Emicizumab, a bispecific monoclonal antibody for hemophilia A (HA), has strong pharmacodynamic effects in several coagulation assays resulting in dosing difficulties with Factor VIII (FVIII) concentrates during bleeding emergencies. MATERIALS AND METHODS: Single and multiple regression...

Descripción completa

Detalles Bibliográficos
Autores principales: Hatayama, Yuki, Motokura, Toru, Hosoda, Yuzuru, Suzuki, Sayaka, Namba, Hiroya, Kato, Konami, Kojima, Nao, Horie, Takuya, Iwamoto, Takuya, Yamashita, Noriko, Ichikawa, Hitomi, Fukuda, Tetsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Manuscript
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894944/
https://www.ncbi.nlm.nih.gov/pubmed/35225012
http://dx.doi.org/10.1177/10760296221082992

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894944/
https://www.ncbi.nlm.nih.gov/pubmed/35225012
http://dx.doi.org/10.1177/10760296221082992

Ejemplares similares